Let's change the rhythm of patient care together

Lindy's suspension technology is validated by a global licensing agreement and currently under evaluation by multiple additional pharma collaborators. Whether you're exploring new molecular entities, lifecycle management opportunities, or high-dose reformulation strategies, we offer flexible partnership structures designed to meet your program's needs.

Partner With Us

Lindy Biosciences Enters Licensing and Collaboration Agreement with Novartis for Multi-Target Drug Delivery Innovation

Read the Full Announcement

Lindy's suspensions give patients back their rhythm. Instead of hours in an infusion chair, a single subcutaneous injection — self-administered at home in under 20 seconds. Better compliance. Better quality of life. Less frequent dosing. Uninterrupted daily living.

Reducing IV infusion dependency lowers administration costs, reduces demand on clinical staff time, and improves resource efficiency across the system. Self-administered subcutaneous injection is the lower-cost, higher-compliance path forward.

Lindy's suspensions are a platform technology — applicable to new molecules and life-cycle management alike. They extend product life cycles, support biosimilar and biobetter development, and reduce time-to-clinic through a proven, reproducible formulation process. Lindy's suspensions also enable high-dose subcutaneous delivery for biologics that currently require IV infusion.

Flexible structures.

Built around your program.

Every partnership is different. We tailor our engagement structure to fit where you are in development — whether that's an initial feasibility assessment or an ongoing development program through IND-enabling studies and clinical manufacturing.

Partner With Us

We meet you where you are.

Whether you're evaluating a new biologic for subcutaneous delivery, exploring life-cycle management for an existing asset, or looking to expand a biosimilar or biobetter program — Lindy Biosciences has a partnership structure to fit.

New molecular entities

Life-cycle management

Biosimilars & biobetters

High-dose reformulation

A technology in demand.

Lindy's suspension technology is currently under evaluation by multiple leading pharmaceutical companies — exploring applications across new molecules and life-cycle management. We're actively pursuing additional licensing agreements. If your company is evaluating subcutaneous delivery options for high-dose biologics, we'd like to talk.

Thanks — we'll be in touch. Your message has been sent to our Business Development team.

Oops! Something went wrong while submitting the form.

Ready to explore a partnership?

Contact our Business Development team to discuss feasibility assessments, licensing, or development programs.

Primary BD contact

Neil Jones, VP, Corporate Strategic Partnerships

info@lindybio.com

Phone

919-765-8700

Address

627 Davis Drive, Suite 400, Morrisville, NC 27560